Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis.

BMC Pulm Med · 2020 · PMC7216337 · PMID 32393215

Europe PMC DOI

hedged sentence

0.0790

closest p · 1.6× alpha

0.0790

boldest claim

The sentences

tendency towards significancep = 0.079so close (0.05 < p ≤ 0.1)

Overall, the majority of subgroup analyses showed a higher rate of responders for revefenacin than for placebo, with the odds of response significantly greater among the severe airflow obstruction subgroup, odds ratio 2.37 (95% confidence intervals 1.10–5.08, p = 0.027), and a tendency towards significance in the 2011 GOLD D subgroup, odds ratio 1.95 (95% confidence intervals 0.93–4.09, p = 0.079).

also in 349 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.